Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:2671
Name transitional cell carcinoma
Definition A carcinoma that derives_from transitional epithelial cells.
Source DiseaseOntology.org
Alt Ids DOID:3995
Path disease disease of cellular proliferation cancer cell type cancer carcinoma transitional cell carcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR3 dec exp FGFR3 wild-type HRAS G12V AZ8010 transitional cell carcinoma decreased response detail...
FGFR3 dec exp FGFR3 wild-type HRAS G12V Fexagratinib transitional cell carcinoma resistant detail...
FGFR3 S249C FGFR3 over exp PD173074 transitional cell carcinoma sensitive detail...
FGFR3 over exp Fexagratinib transitional cell carcinoma sensitive detail...
FGFR3 over exp AZ8010 transitional cell carcinoma sensitive detail...
FGFR3 dec exp FGFR3 wild-type HRAS G12V PD173074 transitional cell carcinoma resistant detail...
NRAS mutant Trametinib transitional cell carcinoma decreased response detail...
HRAS mutant Trametinib transitional cell carcinoma resistant detail...
FGFR3 mutant Infigratinib transitional cell carcinoma sensitive detail...
FGFR3 fusion Infigratinib transitional cell carcinoma sensitive detail...
PTEN loss Everolimus transitional cell carcinoma predicted - resistant detail...
FGFR1 amp Buparlisib + Fexagratinib transitional cell carcinoma sensitive detail...
FGFR3 mutant Docetaxel + Vofatamab transitional cell carcinoma predicted - sensitive detail...
FGFR3 fusion Docetaxel + Vofatamab transitional cell carcinoma predicted - sensitive detail...
FGFR1 mutant Erdafitinib transitional cell carcinoma predicted - sensitive detail...
FGFR3 mutant Erdafitinib transitional cell carcinoma sensitive detail...
FGFR3 V555L Infigratinib transitional cell carcinoma resistant detail...
FGFR3 V555M FGFR3 L608V Infigratinib transitional cell carcinoma predicted - resistant detail...
FGFR3 V555M Infigratinib transitional cell carcinoma resistant detail...
FGFR3 R248C Erdafitinib transitional cell carcinoma sensitive detail...
FGFR3 S249C Erdafitinib transitional cell carcinoma sensitive detail...
FGFR3 G370C Erdafitinib transitional cell carcinoma sensitive detail...
FGFR3 Y373C Erdafitinib transitional cell carcinoma sensitive detail...
FGFR3 mutant Nivolumab transitional cell carcinoma no benefit detail...
FGFR3 mutant Atezolizumab transitional cell carcinoma no benefit detail...
FGFR3 fusion Erdafitinib transitional cell carcinoma predicted - sensitive detail...
FGFR2 fusion Erdafitinib transitional cell carcinoma predicted - sensitive detail...
HRAS act mut Tipifarnib transitional cell carcinoma predicted - sensitive detail...
HRAS mutant Tipifarnib transitional cell carcinoma predicted - sensitive detail...
ARID1B inact mut unspecified immune checkpoint inhibitor transitional cell carcinoma not predictive detail...
SMARCA4 inact mut unspecified immune checkpoint inhibitor transitional cell carcinoma not predictive detail...
SMARCB1 inact mut unspecified immune checkpoint inhibitor transitional cell carcinoma not predictive detail...
PBRM1 inact mut unspecified immune checkpoint inhibitor transitional cell carcinoma not predictive detail...
ARID2 inact mut unspecified immune checkpoint inhibitor transitional cell carcinoma not predictive detail...
TSC1 R500* TSC1 LOH Buparlisib transitional cell carcinoma predicted - sensitive detail...
TSC1 S331Efs*10 TSC1 LOH Buparlisib transitional cell carcinoma predicted - sensitive detail...
PIK3CA amp TSC1 LOH Buparlisib transitional cell carcinoma predicted - sensitive detail...
PTEN LOH Buparlisib transitional cell carcinoma predicted - sensitive detail...
PIK3CA H1047R Buparlisib transitional cell carcinoma no benefit detail...
PIK3CA E542K TSC1 LOH Buparlisib transitional cell carcinoma no benefit detail...
TSC1 Y185* Buparlisib transitional cell carcinoma no benefit detail...
TSC1 R424fs Buparlisib transitional cell carcinoma no benefit detail...
TSC1 Q516* Buparlisib transitional cell carcinoma no benefit detail...
TSC1 inact mut Sapanisertib transitional cell carcinoma no benefit detail...
TSC2 inact mut Sapanisertib transitional cell carcinoma no benefit detail...
FGFR3 S249C Pemigatinib transitional cell carcinoma predicted - sensitive detail...
FGFR3 S249C Futibatinib transitional cell carcinoma predicted - sensitive detail...
ATM inact mut Durvalumab + Olaparib transitional cell carcinoma predicted - sensitive detail...
FGFR1 over exp Rogaratinib transitional cell carcinoma no benefit detail...
FGFR3 over exp Rogaratinib transitional cell carcinoma no benefit detail...
FGFR3 act mut FGFR3 over exp Rogaratinib transitional cell carcinoma predicted - sensitive detail...
FGFR2 mutant Cetrelimab + Erdafitinib transitional cell carcinoma predicted - sensitive detail...
FGFR3 mutant Cetrelimab + Erdafitinib transitional cell carcinoma predicted - sensitive detail...
FGFR3 R248C Dasatinib + PD173074 transitional cell carcinoma sensitive detail...
FGFR3 R248C Dasatinib + Infigratinib transitional cell carcinoma sensitive detail...
FGFR3 S249C PIK3CA E545K Erdafitinib + Pictilisib transitional cell carcinoma sensitive detail...
FGFR3 S249C Erdafitinib + Gefitinib transitional cell carcinoma sensitive detail...
FGFR3 S249C PIK3CA E545A Erdafitinib transitional cell carcinoma predicted - sensitive detail...
FGFR3 S249C FGFR3 N540K PIK3CA E545K Erdafitinib transitional cell carcinoma predicted - resistant detail...
FGFR3 S249C FGFR3 V553L Pemigatinib transitional cell carcinoma not predictive detail...
FGFR3 S249C FGFR3 V555L Erdafitinib transitional cell carcinoma predicted - resistant detail...
FGFR3 S249C FGFR3 amp PTEN C136fs Erdafitinib transitional cell carcinoma predicted - resistant detail...
FGFR3 fusion Pemigatinib transitional cell carcinoma sensitive detail...
FGFR3 act mut Pemigatinib transitional cell carcinoma sensitive detail...
FGFR3 S249C FGFR3 V553M FGFR3 V555L Pemigatinib transitional cell carcinoma predicted - resistant detail...
FGFR3 S249C FGFR3 M528I FGFR3 V553M Pemigatinib transitional cell carcinoma predicted - resistant detail...
FGFR3 S249C FGFR3 N540S Pemigatinib transitional cell carcinoma predicted - resistant detail...
FGFR3 Y373C FGFR3 N540K Pemigatinib transitional cell carcinoma predicted - resistant detail...
FGFR3 S249C FGFR3 V555L Pemigatinib transitional cell carcinoma predicted - resistant detail...
FGFR2 R255W FGFR3 S249C FGFR3 V553M FGFR3 K650M Erdafitinib transitional cell carcinoma predicted - resistant detail...
FGFR3 fusion ABSK061 transitional cell carcinoma predicted - sensitive detail...
FGFR1 M532T Pembrolizumab + Pemigatinib transitional cell carcinoma predicted - sensitive detail...
FGFR3 Y373C Pembrolizumab + Pemigatinib transitional cell carcinoma predicted - sensitive detail...
FGFR1 act mut Derazantinib transitional cell carcinoma no benefit detail...
FGFR2 act mut Derazantinib transitional cell carcinoma no benefit detail...
FGFR3 act mut Derazantinib transitional cell carcinoma no benefit detail...
FGFR3 fusion Derazantinib transitional cell carcinoma no benefit detail...
FGFR3 act mut Atezolizumab + Derazantinib transitional cell carcinoma no benefit detail...
FGFR3 fusion Atezolizumab + Derazantinib transitional cell carcinoma no benefit detail...
FGFR3 over exp Atezolizumab + Rogaratinib transitional cell carcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00978250 Phase II 5-Fluoro-2-deoxycytidine + Tetrahydrouridine A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) Completed USA 0
NCT01004224 Phase I Infigratinib A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies Completed USA | TUR | NLD | ITA | ISR | FRA | ESP | DEU | AUT | AUS 4
NCT01920061 Phase I Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) Completed USA | ITA | GBR | ESP | CAN 0
NCT02052778 Phase Ib/II Futibatinib A Study of TAS-120 in Patients With Advanced Solid Tumors Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 4
NCT02393248 Phase Ib/II Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Terminated USA | DNK 0
NCT02501096 Phase Ib/II Pembrolizumab Lenvatinib Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors Completed USA | NOR | ESP 0
NCT02516241 Phase III Durvalumab + Tremelimumab Carboplatin + Cisplatin + Gemcitabine Durvalumab Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer Active, not recruiting USA | TUR | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUT | AUS 7
NCT02573259 Phase I PF-06801591 A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors Completed USA | POL | BGR 4
NCT02599324 Phase Ib/II Cetuximab + Ibrutinib Ibrutinib + Paclitaxel Everolimus + Ibrutinib Docetaxel + Ibrutinib A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors Completed USA | GBR | ESP 1
NCT02603432 Phase III Avelumab A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) Completed USA | SWE | POL | NZL | NOR | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | CZE | CAN | BRA | BEL | AUS | ARG 9
NCT02628535 Phase I Obrindatamab Safety Study of MGD009 in B7-H3-expressing Tumors Terminated USA | CAN | AUS 0
NCT02660034 Phase I Pamiparib + Tislelizumab The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors Completed USA | NZL | GBR | FRA | ESP | AUS 0
NCT02717156 Phase II Pembrolizumab + sEphB4-HSA Recombinant EphB4-HSA Fusion Protein and Pembrolizumab in Treating Patients With Metastatic or Recurrent Urothelial Cancer That Is Refractory to Certain Chemotherapy Drugs Recruiting USA 0
NCT02736266 Phase II Pembrolizumab Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma Completed ITA 0
NCT02795156 Phase II Cabozantinib Afatinib Regorafenib Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Completed USA 0
NCT02807636 Phase III Atezolizumab + Carboplatin + Gemcitabine Carboplatin + Gemcitabine The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy Completed USA | TUR | SVN | ROU | POL | NLD | ITA | ISR | GRC | GBR | FIN | EST | ESP | CZE | CAN | BRA | BEL | AUS 17
NCT02812420 Phase I Durvalumab + Tremelimumab Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy Active, not recruiting USA 0
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Active, not recruiting USA 1
NCT02856425 Phase I Nintedanib + Pembrolizumab Trial Of Pembrolizumab And Nintedanib (PEMBIB) Recruiting FRA 0
NCT02872714 Phase II Pemigatinib A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) Completed USA | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | BEL 1
NCT02880345 Phase 0 Pembrolizumab RADVAX: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy Withdrawn USA 0
NCT03018405 Phase Ib/II NKR-2 cells A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) Unknown status USA | BEL 0
NCT03029832 Phase II Atezolizumab Atezolizumab + Vonlerolizumab A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy Terminated USA | GBR | CAN | BEL 1
NCT03036098 Phase III Cisplatin + Gemcitabine Ipilimumab + Nivolumab Carboplatin + Gemcitabine Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care Chemotherapy in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer Active, not recruiting USA | TUR | SWE | ROU | POL | NOR | NLD | ITA | ISR | GRC | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | AUS | ARG 9
NCT03047213 Phase II Sapanisertib Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations Active, not recruiting USA 0
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Unknown status USA 0
NCT03091660 Phase III BCG Tokyo-172 Strain Solution BCG solution Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer Active, not recruiting USA 0
NCT03096054 Phase I LY3143921 A CR-UK Phase I Trial of LY3143921 Active, not recruiting GBR 0
NCT03115801 Phase II Atezolizumab Nivolumab A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers Terminated USA 0
NCT03123055 Phase I Atezolizumab + Vofatamab A Study of B-701 in Combination With Atezolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (U22) Terminated USA | TUR | SWE | POL | NLD | ITA | HUN | FRA | ESP | DNK | DEU | BEL 5
NCT03179943 Phase II Atezolizumab + Guadecitabine Overcoming Chechkpoint Inhibitor Resistance With Epigenetic Therapy in Urothelial Cancer Active, not recruiting USA 0
NCT03207867 Phase II Spartalizumab + Taminadenant A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma Terminated USA | NLD | ITA | FRA | ESP | DEU | CZE | CHE | BEL | AUT | AUS | ARG 3
NCT03208712 Phase I Atezolizumab + Radium Ra 223 dichloride Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy Terminated USA 0
NCT03212404 Phase I Cosibelimab Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Recruiting POL | NZL | FRA | ESP | AUS 4
NCT03219333 Phase II Enfortumab vedotin-ejfv A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201) Completed USA | NLD | ITA | FRA | ESP | DEU 2
NCT03236935 Phase I L-NMMA + Pembrolizumab Phase Ib of L-NMMA and Pembrolizumab Active, not recruiting USA 0
NCT03240016 Phase II Nab-paclitaxel + Pembrolizumab Abraxane With Anti-PD1/PDL1 in Cisplatin-ineligible Patients With Advanced Urothelial Cancer Completed USA 0
NCT03241173 Phase Ib/II INCAGN01949 + Ipilimumab INCAGN01949 + Nivolumab INCAGN01949 + Ipilimumab + Nivolumab A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies Completed USA 0
NCT03264066 Phase II Atezolizumab + Cabozantinib A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors Completed USA | HUN | GBR | DEU | BEL 1
NCT03277352 Phase Ib/II Epacadostat + INCAGN01876 + Pembrolizumab INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies Terminated USA 0
NCT03287050 Phase I Pembrolizumab Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma Terminated USA 0
NCT03288545 Phase I Atezolizumab + Enfortumab vedotin-ejfv + Pembrolizumab A Safety Study of Enfortumab Vedotin Plus Immune Checkpoint Inhibitor Therapy for Patients With Urothelial Bladder Cancer (EV-103) Active, not recruiting USA | ITA | FRA | ESP | CAN 1
NCT03289962 Phase I Autogene cevumeran Atezolizumab + Autogene cevumeran A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors Active, not recruiting USA | SWE | NLD | GBR | ESP | DEU | CAN | BEL 0
NCT03311334 Phase I Atezolizumab + DSP-7888 DSP-7888 + Nivolumab A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors Terminated USA | CAN 0
NCT03317496 Phase II Avelumab + Cisplatin + Gemcitabine Avelumab + Carboplatin + Pemetrexed Disodium Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies Terminated USA | ITA | HUN | GBR | ESP | CZE | CAN | AUS 0
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Completed USA 0
NCT03330405 Phase II Avelumab + Talazoparib Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors Terminated USA | HUN | GBR | DNK | CAN | BEL | AUS 2
NCT03339843 Phase II Abemaciclib Multiorgan Metabolic Imaging Response Assessment of Abemaciclib (MiMe-A) Completed FRA | BEL 0
NCT03343613 Phase I LY3300054 + LY3381916 LY3381916 A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors Terminated USA | ITA | FRA | ESP | DNK | BEL 0
NCT03361228 Phase Ib/II Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors Terminated USA 0
NCT03363776 Phase Ib/II BMS-986277 BMS-986277 + Nivolumab An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers Terminated USA | CAN 0
NCT03390504 Phase III Pembrolizumab Erdafitinib Docetaxel + Vinflunine A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (THOR) Active, not recruiting USA | TUR | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BGR | BEL | AUT | AUS | ARG 8
NCT03407976 Phase Ib/II Pembrolizumab + Rivoceranib Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies Terminated USA 0
NCT03409458 Phase Ib/II Avelumab + Imifoplatin A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1) Completed USA | CHE 0
NCT03410927 Phase Ib/II TAS0728 A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities Terminated USA | GBR | FRA | ESP 0
NCT03416335 Phase Ib/II DSP-0509 DSP-0509 + Pembrolizumab A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile Terminated USA 0
NCT03419130 Phase II Pembrolizumab Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer Withdrawn USA 0
NCT03425201 Phase Ib/II Cabozantinib + Niraparib Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA) (NICARAGUA) Completed ESP 0
NCT03435640 Phase Ib/II NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies Terminated USA 0
NCT03448718 Phase II Olaparib Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations Completed USA 0
NCT03449381 Phase I BI 907828 This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) Active, not recruiting USA | SWE | POL | ISR | ESP | DNK | DEU | CAN | BEL 2
NCT03451331 Phase II Carboplatin + Gemcitabine + Nivolumab Gemcitabine + Nivolumab + Oxaliplatin Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer Completed USA 0
NCT03472560 Phase II Avelumab + Axitinib A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF) Terminated USA | POL | ITA | HUN | ESP 3
NCT03473743 Phase Ib/II Cetrelimab + Erdafitinib A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene Alterations Active, not recruiting USA | TUR | POL | ITA | GBR | FRA | ESP | BRA | BEL 4
NCT03474107 Phase III Enfortumab vedotin-ejfv Docetaxel + Paclitaxel + Vinflunine A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BEL | AUT | AUS | ARG 5
NCT03486197 Phase II Pembrolizumab Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma Terminated USA 0
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Completed USA 0
NCT03523572 Phase I Nivolumab + Trastuzumab deruxtecan Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer Unknown status USA | ITA | GBR | FRA | ESP | DEU | BEL 0
NCT03525795 Phase Ib/II CPI-1205 + Ipilimumab ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors Completed USA 0
NCT03528694 Phase III BCG solution + Durvalumab BCG solution Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer Active, not recruiting POL | NLD | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 2
NCT03534804 Phase II Cabozantinib + Pembrolizumab Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab) Completed USA 0
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Completed USA 0
NCT03547973 Phase II Sacituzumab govitecan-hziy Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer Recruiting USA | TUR | ITA | GRC | GBR | FRA | ESP | DEU 1
NCT03590054 Phase I Abexinostat + Pembrolizumab Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies Completed USA 0
NCT03606174 Phase II Nivolumab + Sitravatinib Sitravatinib and Nivolumab in Urothelial Carcinoma Study Terminated USA 0
NCT03621982 Phase I Camidanlumab tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Terminated USA | GBR | BEL 0
NCT03633110 Phase Ib/II GEN-009 GEN-009 + Nivolumab Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine Completed USA 0
NCT03639714 Phase Ib/II GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab A Study of a Personalized Neoantigen Cancer Vaccine Completed USA | AUS 0
NCT03666273 Phase I BAY1905254 BAY1905254 + Pembrolizumab A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254 Completed USA 0
NCT03674424 Phase II Avelumab + Gemcitabine + Paclitaxel Avelumab + Cisplatin + Doxorubicin + Methotrexate + Vinblastine Avelumab Avelumab + Cisplatin + Gemcitabine Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial) (AURA) Active, not recruiting FRA | BEL 0
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Active, not recruiting USA | AUS 4
NCT03679767 Phase II Retifanlimab A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) Completed USA | ROU | POL | ITA | HUN | FRA | ESP | AUT 0
NCT03682289 Phase II Ceralasertib + Olaparib Olaparib Phase II Trial of AZD6738 Alone and in Combination With Olaparib Recruiting USA 0
NCT03693612 Phase Ib/II GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors Completed USA | CAN | AUS 0
NCT03744793 Phase II Avelumab + Pemetrexed Disodium Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer Active, not recruiting USA 0
NCT03752398 Phase I Izuralimab A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) Completed USA 0
NCT03758781 Phase I Cyclophosphamide + IRX-2 + Nivolumab IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors Completed USA 0
NCT03785925 Phase II Nivolumab + NKTR-214 A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer (PIVOT-10) Completed USA | TUR | NLD | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DEU | CAN | BEL | AUS | ARG 3
NCT03792724 Phase Ib/II Nivolumab + Urelumab Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors (INTRUST) Unknown status ESP 0
NCT03809624 Phase II INBRX-105 INBRX-105 + Pembrolizumab Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (PDL1x41BB) Terminated USA 0
NCT03815682 Phase I Pembrolizumab + RPTR-147 RPTR-147 RPTR-147 in Patients With Selected Solid Tumors and Lymphomas Terminated USA 0
NCT03836352 Phase II Maveropepimut-S + Pembrolizumab Cyclophosphamide + Maveropepimut-S + Pembrolizumab Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors Active, not recruiting USA | CAN 0
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Completed USA 0
NCT03854474 Phase Ib/II Pembrolizumab + Tazemetostat Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma Active, not recruiting USA | CAN 0
NCT03894618 Phase I SL-279252 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Completed USA | ESP | CAN | BEL 0
NCT03915405 Phase I Avelumab + KHK2455 KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer Terminated USA | ESP 0
NCT03917381 Phase Ib/II GEN1046 GEN1046 Safety Trial in Patients With Malignant Solid Tumors Active, not recruiting USA | TUR | POL | ITA | ISR | HUN | ESP | CZE 2
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Completed USA | FRA | BEL | AUS 1
NCT03964233 Phase I BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) Active, not recruiting USA | NLD | HUN | GBR | FRA | ESP | DEU | BEL | AUS 2
NCT03970382 Phase I NeoTCR-P1 T-cells + Nivolumab NeoTCR-P1 T-cells A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors Suspended USA 0
NCT03973333 Phase Ib/II Atezolizumab + IMC-C103C IMC-C103C Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab Withdrawn USA | GBR | ESP 0
NCT03986606 Phase I PSB205 A Study of PSB205 in Subjects With Advanced Solid Tumors Unknown status USA 0
NCT03989362 Phase II Ipilimumab + Vopratelimab Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer (EMERGE) Completed USA | CAN 0
NCT03990233 Phase I Effi-DEM Effi-DEM + Ezabenlimab A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours Active, not recruiting FRA | BEL 0
NCT03992131 Phase Ib/II Lucitanib + Rucaparib Rucaparib + Sacituzumab govitecan-hziy A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR) Terminated USA 0
NCT04003610 Phase II Pembrolizumab + Pemigatinib Pembrolizumab Carboplatin + Gemcitabine Pemigatinib Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) Terminated USA | SVK | ROU | POL | ITA | IRL | GBR | FRA | FIN | ESP | DEU | CAN | BEL | AUT 2
NCT04007744 Phase I Pembrolizumab + Sonidegib Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors Recruiting USA 0
NCT04044859 Phase I afamitresgene autoleucel afamitresgene autoleucel + Pembrolizumab afamitresgene autoleucel + Nivolumab ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) Recruiting USA | ESP | CAN | BEL 0
NCT04095273 Phase I Elimusertib + Pembrolizumab Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Completed USA | GBR | ESP | DEU | CHE 0
NCT04096638 Phase I Nivolumab + SB 11285 SB 11285 Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Completed USA 0
NCT04114136 Phase II Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies Recruiting USA 0
NCT04149574 Phase III BCG solution + Nivolumab BCG solution A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8) Terminated USA | SWE | NLD | ITA | ISR | GRC | FRA | ESP | DEU | CAN | BRA | AUT | AUS | ARG 3
NCT04152018 Phase I PF-06801591 + PF-06940434 PF-06940434 Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. Active, not recruiting USA | SVK | AUS 2
NCT04158700 Phase Ib/II LY3200882 + Pembrolizumab A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer Withdrawn USA | FRA | ESP 0
NCT04169841 Phase II Durvalumab + Olaparib + Tremelimumab Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR) Active, not recruiting FRA 0
NCT04173338 Phase I Cabozantinib + Pemetrexed Disodium Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma Terminated USA 0
NCT04198766 Phase I INBRX-106 INBRX-106 + Pembrolizumab Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Recruiting USA 0
NCT04200963 Phase I KYN-175 KYN-175 in Patients With Advanced or Metastatic Solid Tumors and Urothelial Carcinoma Completed USA 0
NCT04223856 Phase III Carboplatin + Enfortumab vedotin-ejfv + Pembrolizumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Enfortumab vedotin-ejfv + Pembrolizumab Cisplatin + Enfortumab vedotin-ejfv + Pembrolizumab Enfortumab Vedotin and Pembrolizumab, With or Without Chemotherapy, vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302) Active, not recruiting USA | TUR | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUS | ARG 7
NCT04259450 Phase Ib/II AFM24 Study to Assess AFM24 in Advanced Solid Cancers Completed USA | GBR | ESP | DEU 1
NCT04260802 Phase Ib/II OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Recruiting CAN 0
NCT04282018 Phase Ib/II BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Completed AUS 1
NCT04311710 Phase Ib/II Ipilimumab + Nivolumab Ipilimumab + Nivolumab + rHuPH20 A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U) Terminated USA | NZL | ITA 0
NCT04322643 Phase II Durvalumab Pembrolizumab Avelumab Nivolumab Atezolizumab Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma Completed USA 0
NCT04349280 Phase I Bintrafusp alfa A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer Terminated USA | NLD | FRA | ESP | CAN 0
NCT04383938 Phase Ib/II APR-246 + Pembrolizumab Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies Completed USA 0
NCT04388852 Phase I DS-3201b + Ipilimumab DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers Recruiting USA 0
NCT04423029 Phase Ib/II DF6002 DF6002 + Nivolumab A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | FRA | ESP | AUS 0
NCT04434560 Phase II Ipilimumab + Nivolumab Neoadjuvant Immunotherapy in Brain Metastases Terminated USA 0
NCT04442126 Phase Ib/II NM21-1480 A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors Terminated USA | ESP 1
NCT04452214 Phase I Nidanilimab + Pembrolizumab A Study of the Safety and Tolerance of CAN04 in Combination With Pembrolizumab in Subjects With Solid Tumors Completed USA 0
NCT04486781 Phase II Pembrolizumab + sEphB4-HSA A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma Recruiting USA 0
NCT04491942 Phase I Cisplatin + Elimusertib Cisplatin + Elimusertib + Gemcitabine Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Active, not recruiting USA | CAN 0
NCT04501094 Phase II Bintrafusp alfa A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma Terminated USA 0
NCT04514484 Phase I Cabozantinib + Nivolumab Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Active, not recruiting USA 0
NCT04521413 Phase Ib/II CFI-402411 + Pembrolizumab CFI-402411 Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies Recruiting USA | CAN 1
NCT04527991 Phase III Paclitaxel Docetaxel Vinflunine Sacituzumab govitecan-hziy Study of Sacituzumab Govitecan (IMMU-132) in Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04) Active, not recruiting USA | TUR | SWE | ITA | ISR | IRL | HRV | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BGR | BEL | AUT | AUS 8
NCT04543110 Phase II Durvalumab Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC (RADIANT) Recruiting CAN 0
NCT04561362 Phase Ib/II BT8009 BT8009 + Pembrolizumab Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies Recruiting USA | ITA | GBR | FRA | ESP | CAN 0
NCT04565275 Phase Ib/II ICP-192 A Study of ICP-192 in Patients With Advanced Solid Tumors Recruiting USA | AUS 0
NCT04579224 Phase III Sacituzumab govitecan-hziy Eribulin Gemcitabine Eribulin + Gemcitabine Docetaxel Paclitaxel Comparing the New Anti-cancer Drug Eribulin With or Without Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer Recruiting USA 0
NCT04586244 Phase II Retifanlimab Epacadostat + Retifanlimab Epacadostat An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma (Optimus) Terminated USA | ITA | FRA 0
NCT04601402 Phase I Avelumab + GEN-001 GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy Completed USA 0
NCT04601857 Phase II Futibatinib + Pembrolizumab Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma Active, not recruiting USA | FRA | ESP 0
NCT04602117 Phase I Paclitaxel + Trastuzumab Duocarmazine Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Withdrawn USA 0
NCT04639245 Phase Ib/II MAGE-A1-specific TCR cells + unspecified PD-1 antibody Cyclophosphamide + Fludarabine Atezolizumab + MAGE-A1-specific TCR cells MAGE-A1-specific TCR cells Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer Terminated USA 0
NCT04641871 Phase I Sym021 + Sym023 Sym021 + Sym022 Sym021 in Combination With Either Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies Completed USA | FRA | ESP | CAN 0
NCT04701918 Phase II Pembrolizumab Pembrolizumab And Cryoablation In Urothelial Carcinoma Recruiting USA 0
NCT04717375 Phase Ib/II BND-22 Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors Recruiting USA | ISR | GBR | CAN 0
NCT04787042 Phase Ib/II Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 Recruiting USA 0
NCT04819373 Phase II EIK1001 BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors Completed USA 0
NCT04827576 Phase II Docetaxel + Hu5F9-G4 Study of Magrolimab in Patients With Solid Tumors (ELEVATELung&UC) Terminated USA | POL | GBR | FRA | ESP 0
NCT04856189 Phase Ib/II Pembrolizumab + Selinexor Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma Recruiting USA 0
NCT04863885 Phase Ib/II Ipilimumab + Nivolumab + Sacituzumab govitecan-hziy Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients Active, not recruiting USA 0
NCT04871529 Phase II Avelumab + Carboplatin + Gemcitabine Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL) Suspended USA 0
NCT04878029 Phase I Cabozantinib + Enfortumab vedotin-ejfv Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer Recruiting USA 0
NCT04879329 Phase II Disitamab vedotin Disitamab vedotin + Pembrolizumab A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 Recruiting USA | ITA | ISR | GBR | ESP | CAN | BEL | AUS | ARG 2
NCT04887831 Phase II Cisplatin + Gemcitabine + Trilaciclib Avelumab + Trilaciclib Carboplatin + Gemcitabine + Trilaciclib Avelumab + Cisplatin + Gemcitabine Avelumab + Carboplatin + Gemcitabine Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab (PRESERVE3) Terminated USA | HUN | FRA | ESP 1
NCT04914286 Phase Ib/II GFH018 + Toripalimab-tpzi A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors Completed AUS 1
NCT04925284 Phase I XB002 Nivolumab + XB002 Study of XB002 in Subjects With Solid Tumors (JEWEL-101) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | BEL | AUS 1
NCT04936230 Phase II Atezolizumab Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer Terminated USA 0
NCT04943900 Phase I BMS-986416 + Nivolumab BMS-986416 A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors Active, not recruiting USA | NLD | CAN | BEL | ARG 2
NCT04999202 Phase I BAY2416964 + Pembrolizumab BAY2416964 A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults Active, not recruiting USA | ITA | GBR 1
NCT05006794 Phase I GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Recruiting USA | ISR 0
NCT05014139 Phase I Enfortumab vedotin-ejfv A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) Recruiting USA | GBR | FRA | ESP | DEU | CAN 0
NCT05043714 Phase I NG-641 + Nivolumab Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NEBULA) Active, not recruiting USA | GBR 0
NCT05101070 Phase Ib/II Pembrolizumab + S-531011 Pembrolizumab S-531011 S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (aCCeleR8-001) Recruiting USA 1
NCT05102214 Phase Ib/II HLX301 HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors Recruiting AUS 0
NCT05107427 Phase II Avelumab + MRx0518 Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma (AVENU) Withdrawn USA 0
NCT05107674 Phase I NX-1607 A Study of NX-1607 in Adults With Advanced Malignancies Recruiting USA | GBR 0
NCT05118841 Phase I ZX-4081 Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors Unknown status USA 0
NCT05121948 Phase I HC-7366 A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) Terminated USA 0
NCT05154994 Phase I Belinostat + Durvalumab + Tremelimumab Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma (RESOLVE) Suspended USA 0
NCT05163041 Phase Ib/II BT7480 BT7480 + Nivolumab Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression Recruiting USA | GBR 0
NCT05219435 Phase II Ipilimumab + Nivolumab Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer (VEXILLUM) Recruiting ESP 0
NCT05226117 Phase II Sacituzumab govitecan-hziy Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer Unknown status ITA 0
NCT05229614 Phase II Pembrolizumab Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease (ICONIC) Recruiting ITA | DEU 0
NCT05233436 Phase I PF-07265028 PF-06801591 + PF-07265028 PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors Terminated USA 1
NCT05244551 Phase I ABSK061 A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT05269381 Phase I Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) Recruiting USA 0
NCT05306444 Phase I HBM7008 CLN-418 Study on Subjects With Advanced Solid Tumors Completed USA | AUS 0
NCT05327530 Phase II Avelumab Avelumab + NKTR-255 Avelumab + Sacituzumab govitecan-hziy Avelumab + M6223 A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) Active, not recruiting USA | ITA | GRC | GBR | FRA | ESP | DEU | CAN | BEL | AUS 2
NCT05335941 Phase II Etrumadenant + Pemetrexed Disodium + Zimberelimab A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma Recruiting USA 0
NCT05354323 Phase I NECVAX-NEO1 NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors Recruiting LTU 0
NCT05394337 Phase I Tiragolumab Atezolizumab Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma Recruiting USA 0
NCT05397171 Phase Ib/II AZD8853 A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours Terminated USA | CAN 0
NCT05524545 Phase I Enfortumab vedotin-ejfv + Evorpacept A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07) Recruiting USA 0
NCT05535218 Phase II Pembrolizumab + Sacituzumab govitecan-hziy Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer (SURE-02) Enrolling by invitation ITA 0
NCT05544552 Phase Ib/II TYRA-300 Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations (SURF301) Recruiting USA | FRA | ESP | AUS 0
NCT05548296 Phase Ib/II Prexasertib Gemcitabine + Prexasertib A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Recruiting USA 0
NCT05574504 Phase II Avelumab + Lurbinectedin Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy Withdrawn USA 0
NCT05585034 Phase I Pembrolizumab + XmAb808 Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb808 in Combination With Pembrolizumab in Advanced Solid Tumors Recruiting USA 0
NCT05600127 Phase II Avelumab Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer (CHASIT) Recruiting NLD 0
NCT05614739 Phase I LOXO-435 + Pembrolizumab LOXO-435 A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3 Recruiting USA | NOR | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CAN | AUS 3
NCT05620134 Phase Ib/II JK08 A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer Active, not recruiting ESP | BEL 0
NCT05627063 Phase I ABSK121 A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors Recruiting USA 1
NCT05642780 Phase II Pembrolizumab + SKB264 SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors Recruiting USA | POL | CAN | BEL | AUS 1
NCT05642949 Phase Ib/II MHB036C Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT05645692 Phase II Atezolizumab RO7247669 RO7247669 + Tiragolumab A Study of RO7247669 Alone or in Combination With Tiragolumab vs Atezolizumab in Participants With Untreated Locally Advanced or Metastatic Urothelial Cancer Active, not recruiting USA | TUR | POL | ITA | GRC | GBR | FRA | ESP | DNK | DEU | BRA | AUS 3
NCT05683418 Phase I TOS-358 A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors Recruiting USA 0
NCT05687721 Phase Ib/II Avelumab + Copanlisib Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer Not yet recruiting USA 0
NCT05714553 Phase Ib/II Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Recruiting GBR 0
NCT05719558 Phase I ASP1002 A Study of ASP1002 in Adults for Treatment of Solid Tumors Recruiting USA 0
NCT05733000 Phase II CPI-613 + Gemcitabine + Hydroxychloroquine CPI-613 + Hydroxychloroquine CPI-613 + Gemcitabine CPI-613 + Fluorouracil + Hydroxychloroquine CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Recruiting USA 0
NCT05826600 Phase I OMX-0407 A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically Recruiting ESP | BEL 0
NCT05841563 Phase I PM54 Clinical Trial of PM54 in Advanced Solid Tumors Patients. Recruiting USA | ESP | BEL 0
NCT05845814 Phase Ib/II Enfortumab vedotin-ejfv + MK-4280A Enfortumab vedotin-ejfv + MK-7684A Enfortumab vedotin-ejfv + Pembrolizumab A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) Active, not recruiting USA | NLD | ITA | ISR | GBR | FRA | ESP | CAN | AUS 3
NCT05875168 Phase Ib/II DS-3939a First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors Recruiting USA | FRA | ESP | BEL 1
NCT05879822 Phase II INCB099280 A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive Active, not recruiting TUR | ROU | NZL | HUN | GRC | BRA 3
NCT05902988 Phase Ib/II VLS-1488 A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer Recruiting USA 0
NCT05904496 Phase I BGB-30813 BGB-30813 + Tislelizumab A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors Active, not recruiting USA | ESP | AUS 0
NCT05923190 Phase II Enfortumab vedotin-ejfv Enfortumab vedotin-ejfv + Pembrolizumab Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma Recruiting USA 0
NCT05929235 Phase I FX-909 A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma Recruiting USA 0
NCT05934539 Phase Ib/II ALG.APV-527 ALG.APV-527 First-in-human Study Recruiting USA 0
NCT05947474 Phase I ORB-011 ORB-011 In Patients With Advanced Solid Tumors (ORB) Recruiting USA 0
NCT05958199 Phase I NPX267 Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 Recruiting USA 0
NCT05969041 Phase I MT-302 Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony) Recruiting AUS 0
NCT05985083 Phase I IMM47 A Study Of IMM47 In Subjects With Advanced Solid Tumors Recruiting AUS 0
NCT06018116 Phase II Bicalutamide A Canadian Phase II Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer (CANUCK-01) Withdrawn CAN 0
NCT06034860 Phase I MT-8421 + Nivolumab MT-8421 Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types Terminated USA 0
NCT06036121 Phase I ADRX-0706 A Study of ADRX-0706 in Select Advanced Solid Tumors Recruiting USA 1
NCT06047379 Phase Ib/II NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Recruiting USA 0
NCT06108050 Phase I JZP898 + Pembrolizumab JZP898 JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors Recruiting USA 0
NCT06225596 Phase II Avelumab + Carboplatin + Gemcitabine Avelumab + Cisplatin + Gemcitabine BT8009 BT8009 + Pembrolizumab Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting USA | TUR | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | ARG 5
NCT06238479 Phase I LY4101174 A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors Recruiting USA | ESP | BEL | AUS 1
NCT06285097 Phase I PF-07820435 PF-06801591 + PF-07820435 A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors Active, not recruiting USA 2
NCT06293898 Phase I BL-M07D1 Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors Recruiting USA 0
NCT06305767 Phase II Pembrolizumab mRNA-4157 + Pembrolizumab A Study of Pembrolizumab (MK-3475) Plus V940 in Participants With Bladder Cancer Post-Radical Resection (V940-005) Recruiting USA | TUR | SWE | POL | NZL | ITA | GBR | FRA | ESP | DEU | CAN | AUS 4
NCT06318871 Phase I CIML-NK cells + Nogapendekin alfa inbakicept A Phase 0 Pilot Study of Memory-like Natural Killer (NK) Cell Immune Therapy in Combination With N-803 in Patients With Renal Cell Carcinoma or Urothelial Carcinoma Recruiting USA 0
NCT06330064 Phase II Ifinatamab deruxtecan A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) Recruiting USA | TUR | POL | NLD | ITA | IRL | FRA | ESP | DEU | BRA | BEL | AUS | ARG 5
NCT06331598 Phase II Atezolizumab Atezolizumab + Tiragolumab A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator) Recruiting ESP 0
NCT06332755 Phase I LB-LR1109 Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors (LB-LR1109) Recruiting USA 0
NCT06424717 Phase II Avelumab + M1774 Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder) Withdrawn 0
NCT06448364 Phase I PF-06801591 + PF-07329640 PF-07329640 Bevacizumab + PF-07329640 A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination (LTbR) Terminated USA 1
NCT06451497 Phase I ZM008 Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06465069 Phase I LY4052031 A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NEXUS-01) Recruiting USA | GBR | ESP 1
NCT06483334 Phase Ib/II Enfortumab vedotin-ejfv + Pembrolizumab + Sacituzumab govitecan-hziy Enfortumab vedotin-ejfv + Sacituzumab govitecan-hziy A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) Recruiting USA | NLD | ISR | GBR | ESP | CAN 2
NCT06514651 Phase I MAQ-001 Ipilimumab + MAQ-001 MAQ-001 in Patients With Advanced Solid Tumors Recruiting FRA 0
NCT06534983 Phase II Nivolumab Autogene cevumeran + Nivolumab A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC) (IMCODE004) Recruiting USA | ITA | DEU | CAN | AUS 0
NCT06548672 Phase I BC3195 A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer Recruiting USA 0
NCT06580938 Phase I PF-07921585 PF-06801591 + PF-07921585 A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer Recruiting USA 0
NCT06582017 Phase I QXL138AM Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma Recruiting USA 0
NCT06644755 Phase I DS-2243a First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors Recruiting USA 0
NCT06660654 Phase II Raludotatug deruxtecan A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) Not yet recruiting USA 0
NCT06697197 Phase Ib/II BMS-986482 + Nivolumab and relatlimab-rmbw Bevacizumab + BMS-986482 BMS-986482 BMS-986298 + BMS-986482 A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors Not yet recruiting USA 0